Noven's Stavzor receives US nod for three indications
This article was originally published in Scrip
Executive Summary
Noven has received approval from the US FDA for its bipolar disorder drug Stavzor (valproic acid delayed release capsules) for the treatment of three separate indications, and will be launched this month.